生物活性 | Citric acid trisodium is a natural preservative and food tartness enhancer. Citric acid trisodium inducesapoptosisand cell cycle arrest at G2/M phase and S phase. Citric acid trisodium cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid trisodium causes renal toxicity in mice[1][2][3]. |
IC50& Target | Human Endogenous Metabolite |
|
体外研究 (In Vitro) | Citric acid trisodium (0-12.5 mM; 24 h) shows antiproliferative activity in a dose dependent manner[3]. Citric acid trisodium (12.5 mM; 72 h) induces apoptosis and cell cycle arrest at G2/M phase and S phase in a dosedependent manner[3]. Citric acid trisodium (12.5 mM; 48 h) increases the expression of FAS, BAX, BID, AIF, EndoG, cytochrome c, PARP, GADD153, GRP78 and caspase-3, -8, -9, and decreases of BCL-2 and BCL-Xl[3].
Cell Viability Assay[3] Cell Line: | HaCaT cells | Concentration: | 0, 2.5, 5, 7.5, 10, 12.5 mM | Incubation Time: | 24 h | Result: | Inhibited the cell viability in a dose dependent manner. |
Cell Cycle Analysis[3] Cell Line: | HaCaT cells | Concentration: | 12.5 mM | Incubation Time: | 0, 12, 24, 48, 72 h | Result: | Induced apoptosis and cell cycle arrest at G2/M phase and S phase in a dosedependent manner. |
Western Blot Analysis[3] Cell Line: | HaCaT cells | Concentration: | 12.5 mM | Incubation Time: | 12, 24, 48 h | Result: | Increased the expression of FAS, BAX, BID, AIF, EndoG, cytochrome c, PARP, GADD153, GRP78 and caspase-3, -8, -9, and decreased of BCL-2 and BCL-Xl. |
|
体内研究 (In Vivo) | Citric acid trisodium (120, 240, and 480 mg/kg; i.p.) significantly decreases GSH-Px activity and induces an increase in the MDA (malonyldialdehyde) levels in mouse liver[1]. Citric acid trisodium (120, 240, and 480 mg/kg; i.p.) induces apoptosis by increases caspase-3 activity in a dose-dependent manner in mouse hepatocytes[1]. Citric acid trisodium (120, 240, and 480 mg/kg; i.p.; weekly for 3 weeks) causes renal toxicity in mice[2].
Animal Model: | 20 g male Kunming mice[2] | Dosage: | 120, 240, 480 mg/kg | Administration: | I.p.; weekly for 3 weeks | Result: | T-SOD and GSH-Px activities in the treated groups decreased with increasing doses of citric acid, NOS activity tended to increase, and H2O2 and MDA contents gradually decreased. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 100 mg/mL(387.49 mM;Need ultrasonic) 配制储备液 1 mM | 3.8749 mL | 19.3746 mL | 38.7492 mL | 5 mM | 0.7750 mL | 3.8749 mL | 7.7498 mL | 10 mM | 0.3875 mL | 1.9375 mL | 3.8749 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 |